Biblio

80 resultats trouvés
Filtres: Auteur is Andre, Thierry  [Clear All Filters]
2
Magne N, Sabatier R, Wislez M, Andre T, Rodrigues M, Herve L, Thiery-Vuillemin A, Penel N, Bouleuc C, Bay J-O.  2020.  2019 international oncology news: A compendium. BULLETIN DU CANCER. 107:148-156.
A
Senellart H, Samalin E, Castan F, Borg C, Adenis A, de la Fouchardiere C, Malka D, Guerin-Meyer V, Francois E, Ben Abdelghani M et al..  2016.  A multi-centric randomized phase II trial evaluating dual targeting of the EGFR with cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer (UCGI 25: A UNICANCER trial).. JOURNAL OF CLINICAL ONCOLOGY. 34
Bachet J-B, Chibaudel B, Bonnetain F, Validire P, Hammel P, Andre T, Louvet C, Grp GERCOR.  2015.  A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial. BMC CANCER. 15:653.
Rousseau B, Boukerma AKhaled, Henriques J, Cohen R, Lucidarme O, Borg C, Tournigand C, Kim SChong Hun, Bachet J-B, Mazard T et al..  2019.  Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO).. JOURNAL OF CLINICAL ONCOLOGY. 37
Vassal G, Ledeley M-C, Tournigand C, Aparicio T, Ray-Coquard I, Taillandier L, Escudier B, You B, Goncalves A, Bohas CLombard et al..  2015.  Activity of crizotinib in relapsed MET amplified malignancies: Results of the French AcSe Program.. JOURNAL OF CLINICAL ONCOLOGY. 33
Andre T, De Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JLuc et al..  2015.  Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. JOURNAL OF CLINICAL ONCOLOGY. 33:4176+.
Jary M, Borg C, Bouche O, Kim S, Andre T, Bennouna J.  2015.  Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense? BULLETIN DU CANCER. 102:758-771.
Michel P, Boige V, Andre T, Aparicio T, Bachet JBaptiste, Dahan L, Guimbaud R, Lepage C, Manfredi S, Tougeron D et al..  2018.  Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). DIGESTIVE AND LIVER DISEASE. 50:305-307.
Chibaudel B, Henriques J, Rakez M, Brenner B, Kim TWon, Martinez-Villacampa M, Gallego-Plazas J, Cervantes A, Shim K, Jonker D et al..  2020.  Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer A Secondary Analysis of the AVANT Trial. JAMA NETWORK OPEN. 3:e2020425.
Auclin E, Taieb J, Lepage C, Aparicio T, Faroux R, Mini E, Folprecht G, Salazar R, Banzi M, Louvet C et al..  2018.  Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies.. JOURNAL OF CLINICAL ONCOLOGY. 36
Auclin E, Andre T, Taieb J, Banzi M, Van Laethem J-L, Tabernero J, Hickish T, de Gramont A, Vernerey D.  2019.  Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial. BRITISH JOURNAL OF CANCER. 121:312-317.
Kim S, Buecher B, Andre T, Jary M, Bidard F-C, Ghiringhelli F, Francois E, Taieb J, Smith D, de la Fouchardiere C et al..  2020.  Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. BMC CANCER. 20
Taieb J, Andre T, Hajbi FEl, Barbier E, Toullec C, Kim S, Bouche O, Di Fiore F, Chauvenet M, Perrier H et al..  2021.  Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. DIGESTIVE AND LIVER DISEASE. 53:318-323.
B
Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mesange P, Lledo G, Viret F, Ramee J-F, Tubiana-Mathieu N et al..  2015.  Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. LANCET ONCOLOGY. 16:1493-1505.
C
Auclin E, Taieb J, Lepage C, Aparicio T, Faroux R, Mini E, Folprecht G, Salazar R, Benetkiewicz M, Banzi M et al..  2019.  Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 28:1153-1161.
Cohen R., Buhard O., Cervera P., Hain E., Dumont S., Bardier A., Bachet J.-B, Gornet J.-M, Lopez-Trabada D., Dumont S. et al..  2017.  Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. EUROPEAN JOURNAL OF CANCER. 86:266-274.
D
Taieb J, Benhaim L, Puig PLaurent, Le Malicot K, Emile JFrancois, Geillon F, Tougeron D, Manfredi S, Chauvenet M, Taly V et al..  2020.  ?Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial?. DIGESTIVE AND LIVER DISEASE. 52:730-733.
Toulmonde M, Ray-Coquard ILaure, Pulido M, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Thyss A, Bertucci F et al..  2018.  DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group.. JOURNAL OF CLINICAL ONCOLOGY. 36
Kim S, Jary M, Andre T, Vendrely V, Buecher B, Francois E, Bidard F-C, Dumont S, Samalin E, Peiffert D et al..  2017.  Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). BMC CANCER. 17:574.
Kim S, Francois E, Andre T, Samalin E, Jary M, Hajbi FEl, Baba-Hamed N, Pernot S, Kaminsky M-C, Bouche O et al..  2018.  Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. LANCET ONCOLOGY. 19:1094-1106.
E
Fontana E, Meyers J, Sobrero A, Iveson T, Shields AF, Taieb J, Yoshino T, Souglakos I, Smyth EC, Lordick F et al..  2021.  Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. JOURNAL OF CLINICAL ONCOLOGY. 39:4009+.
Shields AFrank, Ou F-S, Paul J, Sobrero AF, Yoshino T, Taieb J, Souglakos I, Shi Q, Kerr R, Labianca R et al..  2018.  Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.. JOURNAL OF CLINICAL ONCOLOGY. 36
Hammel P, Huguet F, Van Laethem J-L, Goldstein D, Glimelius B, Artru P, Borbath I, Bouche O, Shannon J, Andre T et al..  2016.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 315:1844-1853.
Borg C, Mantion G, Boudghene F, Mornex F, Ghiringhelli F, Adenis A, Azria D, Balosso J, Ben Abdelghani M, Bachet JBaptiste et al..  2019.  Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. CLINICAL COLORECTAL CANCER. 18:200+.
Chibaudel B, Bachet J-B, Andre T, Auby D, Desrame J, Deplanque G, Lecaille C, Louvet C, Tournigand C, Lebrun-Ly V et al..  2019.  Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first-line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study. INTERNATIONAL JOURNAL OF ONCOLOGY. 54:1433-1445.

Pages